On Monday, Twist Bioscience Corporation (NASDAQ:TWST) reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents.
Twist Bioscience reported fourth-quarter sales of $84.71 million, up 27% year-over-year, beating the consensus of $82.2 million and the management guidance of $82 million–$83 million.
The company shipped products to approximately 3,562 customers in fiscal 2024, compared to approximately 3,450 in 2023. Twist shipped approximately 772,000 genes in 2024 compared to approximately 634,000 genes a year ago.
Total orders received for the fourth quarter of fiscal 2024 grew 24% to $88.2 million compared to $71.1 million for the same period of fiscal 2023. Gross margin improved to 45.1%, up from 36.6% a year ago.
“As we head into fiscal 2025, we’re building on this momentum as we continue our final push toward achieving adjusted EBITDA breakeven while investing in research and development to deliver precision, efficiency and scalability in products and services that continue to generate profitable growth,” said Emily Leproust, CEO and co-founder of Twist Bioscience.
Adjusted EBITDA for the fourth quarter of fiscal 2024 was $(17.0) million compared to $(26.4) million for the same period of fiscal 2023
Guidance: Twist Bioscience expects fiscal year 2025 sales of $367 million – $377 million, up 17% – 20% year over year, versus a consensus of $371.42 million.
The guidance includes SynBio’s revenue guidance of approximately $142 million – $146 million, up 15% – 18%. NGS revenue of $204 million – $209 million, up 20% – 24%. Biopharma revenue is expected to be approximately $21 million – $22 million, up 5% – 8%.
The gross margin is projected to be approximately 48% for fiscal 2025, with quarterly sequential improvements and a 4QFY25 gross margin of 50%. Adjusted EBITDA of approximately $(60) million to $(65) million for fiscal 2025.
The company expects first-quarter 2025 sales of around $87 million compared to the consensus of $84.47 million.
SynBio’s revenue guidance of approximately $34 million, up 26% year over year. NGS revenue of $48 million, up 22%. Biopharma revenue is expected to be approximately $5 million. Adjusted EBITDA of approximately $(20) million with sequential improvements throughout 2025.
Price Action: TWST stock is up 12.7% at $41.59 at last check Monday.
Illustration of Phrama lab worker created with MidJourney
Read Next:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.